CN115043817A - Sos1蛋白水解调节剂及其制备方法和应用 - Google Patents

Sos1蛋白水解调节剂及其制备方法和应用 Download PDF

Info

Publication number
CN115043817A
CN115043817A CN202210114053.0A CN202210114053A CN115043817A CN 115043817 A CN115043817 A CN 115043817A CN 202210114053 A CN202210114053 A CN 202210114053A CN 115043817 A CN115043817 A CN 115043817A
Authority
CN
China
Prior art keywords
group
alkyl
amino
substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210114053.0A
Other languages
English (en)
Chinese (zh)
Inventor
吕彬华
崔大为
庞旭东
刘连军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Zelgen Biopharmaceutical Co Ltd
Shanghai Zelgen Pharmatech Co Ltd
Original Assignee
Suzhou Zelgen Biopharmaceutical Co Ltd
Shanghai Zelgen Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Zelgen Biopharmaceutical Co Ltd, Shanghai Zelgen Pharmatech Co Ltd filed Critical Suzhou Zelgen Biopharmaceutical Co Ltd
Priority to PCT/CN2022/080000 priority Critical patent/WO2022188819A1/fr
Publication of CN115043817A publication Critical patent/CN115043817A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202210114053.0A 2021-03-09 2022-01-30 Sos1蛋白水解调节剂及其制备方法和应用 Pending CN115043817A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2022/080000 WO2022188819A1 (fr) 2021-03-09 2022-03-09 Modulateur de protéolyse sos1, son procédé de préparation et son application

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2021102573968 2021-03-09
CN202110257396 2021-03-09
CN2021104442415 2021-04-23
CN202110444241 2021-04-23

Publications (1)

Publication Number Publication Date
CN115043817A true CN115043817A (zh) 2022-09-13

Family

ID=83157310

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210114053.0A Pending CN115043817A (zh) 2021-03-09 2022-01-30 Sos1蛋白水解调节剂及其制备方法和应用

Country Status (2)

Country Link
CN (1) CN115043817A (fr)
WO (1) WO2022188819A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115232108A (zh) * 2021-04-23 2022-10-25 上海领泰生物医药科技有限公司 Sos1降解剂及其制备方法和应用
WO2023246656A1 (fr) * 2022-06-23 2023-12-28 北京福元医药股份有限公司 Chimère ciblant la protéolyse sos1, composition, préparation et utilisation associées
WO2024067744A1 (fr) * 2022-09-27 2024-04-04 苏州泽璟生物制药股份有限公司 Quinazoline substituée hétérocyclique, son procédé de préparation et son utilisation
WO2024083255A1 (fr) * 2022-10-21 2024-04-25 上海领泰生物医药科技有限公司 Dérivé d'aminoquinazoline substitué par benzyle ou thiénylméthylène et son utilisation en tant qu'agent de dégradation de sos1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861066C (fr) * 2012-01-12 2024-01-02 Yale University Composes et procedes pour la degradation amelioree de proteines cibles et d'autres polypeptides par une e3 ubiquitine ligase
CN103304572A (zh) * 2012-03-09 2013-09-18 上海医药集团股份有限公司 一类3-氰基喹啉类化合物及其药用组合物和应用
AU2016232705C1 (en) * 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
CN110167928A (zh) * 2016-12-22 2019-08-23 勃林格殷格翰国际有限公司 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物
EP3601267A1 (fr) * 2017-03-21 2020-02-05 Bayer Pharma Aktiengesellschaft 2-méthyl-quinazolines
WO2019140380A1 (fr) * 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Agents de dégradation de protéines et utilisations associées
CA3095494C (fr) * 2018-04-04 2023-11-07 Arvinas Operations, Inc. Modulateurs de proteolyse et procedes d'utilisation associes
CN113527260A (zh) * 2020-04-21 2021-10-22 四川海思科制药有限公司 一种具有降解stat3酶的化合物及其制备方法和药学上的应用
WO2022061348A1 (fr) * 2020-09-16 2022-03-24 Biotheryx, Inc. Agents de dégradation de protéine sos1, compositions pharmaceutiques de ceux-ci, et leurs applications thérapeutiques

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115232108A (zh) * 2021-04-23 2022-10-25 上海领泰生物医药科技有限公司 Sos1降解剂及其制备方法和应用
WO2023246656A1 (fr) * 2022-06-23 2023-12-28 北京福元医药股份有限公司 Chimère ciblant la protéolyse sos1, composition, préparation et utilisation associées
WO2024067744A1 (fr) * 2022-09-27 2024-04-04 苏州泽璟生物制药股份有限公司 Quinazoline substituée hétérocyclique, son procédé de préparation et son utilisation
WO2024083255A1 (fr) * 2022-10-21 2024-04-25 上海领泰生物医药科技有限公司 Dérivé d'aminoquinazoline substitué par benzyle ou thiénylméthylène et son utilisation en tant qu'agent de dégradation de sos1

Also Published As

Publication number Publication date
WO2022188819A1 (fr) 2022-09-15

Similar Documents

Publication Publication Date Title
CN115043817A (zh) Sos1蛋白水解调节剂及其制备方法和应用
CN113666923A (zh) 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
CN110698481B (zh) 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物
CN106922146B (zh) 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物
CN114269741A (zh) 环烷基类和杂环烷基类抑制剂及其制备方法和应用
CN115003304A (zh) 通过泛素蛋白酶体途径降解btk的双官能化合物
KR101828187B1 (ko) 신규 축합 피리미딘 화합물 또는 그 염
CN115043842A (zh) 胺基取代双环类抑制剂及其制备方法和应用
JP7044801B2 (ja) Ｃｄｋ４／６阻害剤
CN115109078A (zh) 嘧啶并吡啶类抑制剂及其制备方法和应用
EP4074710A1 (fr) Composé de pyrazolo[1,5-a]pyridine, son procédé de préparation et son utilisation
CN114835719A (zh) 取代双环并芳杂环胺类抑制剂及其制备方法和应用
CN112778301A (zh) 四氢吡啶并嘧啶类抑制剂及其制备方法和应用
CN112824410A (zh) 氮杂七元环类抑制剂及其制备方法和应用
CN114835703A (zh) 取代嘧啶并吡啶酮类抑制剂及其制备方法和应用
WO2023116934A1 (fr) Régulateur d'hydrolyse de protéine krasg12d, son procédé de préparation et son utilisation
CN110945000A (zh) 含有氨基吡唑并嘧啶的大环化合物及其药物组合物和用途
CN113105448A (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
CN107686477B (zh) 作为cdk4/6抑制剂的新型化合物及其应用
WO2024002373A1 (fr) Inhibiteur de cycle fusionné de pyrimidine substitué, son procédé de préparation et son utilisation
CN113801113A (zh) 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN115215869A (zh) 取代三环类抑制剂及其制备方法和应用
CN115215844A (zh) 取代嘧啶并环类抑制剂及其制备方法和应用
CN114380805A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination